<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) represents one of the most rapidly growing <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in childhood and adolescence </plain></SENT>
<SENT sid="1" pm="."><plain>About 80% of patients now are cured with adequate treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Serious complications at presentation due to <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> or local <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effects are commonly observed </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, a rapid diagnosis with the least invasive procedure enabling the initiation of early and specific therapy is necessary to diminish early fatality or persistent impairment </plain></SENT>
<SENT sid="4" pm="."><plain>In 56 centrally registered patients with NHL, cytomorphologic analyses (FAB criteria) of May-Gr√ºnwald-Giemsa-stained touch imprints or <z:e sem="disease" ids="C0080032" disease_type="Disease or Syndrome" abbrv="">malignant effusions</z:e> and flow cytometric immunophenotyping (EGIL criteria) of fresh cell suspensions with a standardized panel of monoclonal antibodies were performed </plain></SENT>
<SENT sid="5" pm="."><plain>The authors identified 23 patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by the combination of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">FAB L3</z:e> <z:mp ids='MP_0000002'>morphology</z:mp> and a mature B-<z:mp ids='MP_0005384'>cell phenotype</z:mp> and 22 patients with lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by <z:e sem="disease" ids="C0522628" disease_type="Neoplastic Process" abbrv="">FAB L1</z:e>/L2 <z:mp ids='MP_0000002'>morphology</z:mp> and a T-/B-cell precursor phenotype </plain></SENT>
<SENT sid="6" pm="."><plain>They also found 11 patients with large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 3 of them with anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (T-<z:mp ids='MP_0005384'>cell phenotype</z:mp>; NPM/ALK-positive) </plain></SENT>
<SENT sid="7" pm="."><plain>In the remaining 8 patients diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was suspected by the combined use of cytologic and immunophenotypic findings (mature B-<z:mp ids='MP_0005384'>cell phenotype</z:mp>) </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases with available <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> material (n = 42/56) the preliminary diagnosis was confirmed by histopathology </plain></SENT>
<SENT sid="9" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and, in a few cases, some large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> could be classified reliably by cytomorphology and immunophenotyping of freshly obtained <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell material, enabling an early start of specific <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment </plain></SENT>
</text></document>